Create a free research account to view current pricing and place an order.
Mechanism of action
Tirzepatide is a dual GIP and GLP receptor agonist. Combined incretin signaling affects pancreatic insulin secretion, glucagon dynamics, gastric-emptying tone, hypothalamic satiety signaling, and adipocyte nutrient-partitioning pathways.
Half-life & pharmacokinetics
Half-life: Approx. 5-6 days.
Approximate half-life is 5-6 days. Median time to maximum concentration is about 24 hours with a reported range of roughly 8-72 hours; steady state is typically achieved after about 4 weeks of once-weekly administration.
Research dosing reference
2.5-15 mg once weekly; escalate gradually based on tolerance.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 2.5 mg | 50 units |
| 5 mg | 100 units |
| 10 mg | 200 units |
| 15 mg | 300 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
| 20 mg | 2 mL BAC Water | 0.100 mg/unit |
| 30 mg | 3 mL BAC Water preferred for cleaner concentration interpretation | 0.100 mg/unit |
| 60 mg | 3 mL BAC Water preferred for cleaner concentration interpretation | 0.200 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Avoid stacking overlapping incretin agonists unless intentionally structured and clinician supervised. Pathway contrast with GH-axis, mitochondrial, or lipolysis adjuncts is generally cleaner than incretin overlap.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Long-term metabolic protocols should include reassessment every 8-12 weeks: GI tolerance, hydration, appetite adaptation, body-composition response, metabolic markers, and whether escalation is still needed. Avoid continuous escalation without objective review.
Frequently asked questions
What is Tirzepatide and how does it work?
Tirzepatide is a dual GIP and GLP receptor agonist. Combined incretin signaling affects pancreatic insulin secretion, glucagon dynamics, gastric-emptying tone, hypothalamic satiety signaling, and adipocyte nutrient-partitioning pathways.
What is the half-life of Tirzepatide?
Tirzepatide: Approx. 5-6 days. Approximate half-life is 5-6 days. Median time to maximum concentration is about 24 hours with a reported range of roughly 8-72 hours; steady state is typically achieved after about 4 weeks of once-we
How is Tirzepatide reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is Tirzepatide FDA approved?
No. Tirzepatide is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
Tirzepatide product overview · Tirzepatide cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration